Dr Tibor Bakács
Talks covered by this speaker
The Clinically Validated Viral Superinfection Therapy (SIT) Platform Technology May Mitigate Severe Cases of COVID-19 Infections
Categories covered by Dr Tibor
About this Speaker
Dr. Bakacs has 40 years of experience in scientific research. His current interests are (i) viral superinfection treatment (SIT) of hepatitis B and C virus infected patients with unmet needs; (ii) oncolytic Newcastle Disease virus (NDV) therapy of advanced cancer; (iii) therapeutic application of autoimmune T-cells, which are induced by an off-label low-dose immune checkpoint blockade in advanced cancer. Formerly, he was the Head of Immunology at the Hungarian National Institute of Oncology. He spent longer periods abroad, at the Karolinska Institute in Stockholm, Sweden, Christie Hospital in Manchester, UK and the National Cancer Institute (NCI/NIH) in the USA. Currently, he is the Chief Scientific Officer of Superinfection, Pret Therapeutics Ltd, and Lodoco Clinical Ltd. He is consultant at the Department of Probability, Alfred Renyi Institute of Mathematics. Dr. Bakacs authored 75 scientific papers and two patents.